Used in targeted immunotherapy for the treatment of high-risk neuroblastoma, particularly in pediatric patients. It binds to the GD2 disialoganglioside, a surface antigen highly expressed on neuroblastoma cells, enabling immune-mediated destruction through mechanisms like antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Employed in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) to enhance immune activation. Also being investigated in clinical trials for other GD2-expressing cancers such as osteosarcoma and melanoma. Serves as a reference standard in the development and validation of biosimilar antibodies and diagnostic assays.